PharmGen Science Inc - Asset Resilience Ratio
PharmGen Science Inc (004720) has an Asset Resilience Ratio of 0.16% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of PharmGen Science Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how PharmGen Science Inc's Asset Resilience Ratio has changed over time. See PharmGen Science Inc (004720) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down PharmGen Science Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PharmGen Science Inc (004720) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩533.30 Million | 0.16% |
| Total Liquid Assets | ₩533.30 Million | 0.16% |
Asset Resilience Insights
- Limited Liquidity: PharmGen Science Inc maintains only 0.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
PharmGen Science Inc Industry Peers by Asset Resilience Ratio
Compare PharmGen Science Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Roche Holding AG
SW:ROG |
Drug Manufacturers - General | 15.37% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
CSPC Pharmaceutical Group Limited
F:CVG |
Drug Manufacturers - General | 4.64% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.03% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 10.10% |
Annual Asset Resilience Ratio for PharmGen Science Inc (2004–2024)
The table below shows the annual Asset Resilience Ratio data for PharmGen Science Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.15% | ₩532.57 Million ≈ $360.91K |
₩363.45 Billion ≈ $246.31 Million |
-0.01pp |
| 2023-12-31 | 0.16% | ₩531.85 Million ≈ $360.43K |
₩335.92 Billion ≈ $227.65 Million |
-0.01pp |
| 2022-12-31 | 0.17% | ₩531.28 Million ≈ $360.04K |
₩317.39 Billion ≈ $215.09 Million |
-0.07pp |
| 2021-12-31 | 0.24% | ₩531.09 Million ≈ $359.91K |
₩220.32 Billion ≈ $149.31 Million |
-3.10pp |
| 2020-12-31 | 3.34% | ₩4.53 Billion ≈ $3.07 Million |
₩135.54 Billion ≈ $91.86 Million |
-1.19pp |
| 2019-12-31 | 4.53% | ₩4.53 Billion ≈ $3.07 Million |
₩100.03 Billion ≈ $67.79 Million |
-19.43pp |
| 2018-12-31 | 23.96% | ₩23.53 Billion ≈ $15.95 Million |
₩98.19 Billion ≈ $66.54 Million |
-0.61pp |
| 2017-12-31 | 24.57% | ₩16.83 Billion ≈ $11.40 Million |
₩68.48 Billion ≈ $46.41 Million |
-3.37pp |
| 2016-12-31 | 27.95% | ₩17.97 Billion ≈ $12.18 Million |
₩64.30 Billion ≈ $43.58 Million |
+15.85pp |
| 2015-12-31 | 12.10% | ₩5.62 Billion ≈ $3.81 Million |
₩46.45 Billion ≈ $31.48 Million |
+4.81pp |
| 2014-12-31 | 7.29% | ₩3.06 Billion ≈ $2.08 Million |
₩42.04 Billion ≈ $28.49 Million |
+2.43pp |
| 2013-12-31 | 4.86% | ₩1.91 Billion ≈ $1.29 Million |
₩39.33 Billion ≈ $26.65 Million |
+3.65pp |
| 2012-12-31 | 1.21% | ₩515.00 Million ≈ $349.01K |
₩42.61 Billion ≈ $28.88 Million |
-0.44pp |
| 2011-12-31 | 1.64% | ₩704.04 Million ≈ $477.12K |
₩42.82 Billion ≈ $29.02 Million |
-2.50pp |
| 2005-12-31 | 4.14% | ₩2.75 Billion ≈ $1.87 Million |
₩66.47 Billion ≈ $45.04 Million |
-0.77pp |
| 2004-12-31 | 4.92% | ₩2.43 Billion ≈ $1.65 Million |
₩49.49 Billion ≈ $33.54 Million |
+0.37pp |
| 2004-09-30 | 4.55% | ₩2.27 Billion ≈ $1.54 Million |
₩49.90 Billion ≈ $33.82 Million |
-- |
About PharmGen Science Inc
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed i… Read more